NURIX THERAPEUTICS, INC. — Operating Income by Fiscal Year
7 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/df040048-86d0-487c-a11f-fc79e6603d6c/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-285.7M | 2024-12-01 – 2025-11-30 | evidence 0001549595-26-000016 |
| FY 2024 | $-213.0M | 2023-12-01 – 2024-11-30 | evidence 0001549595-25-000016 |
| FY 2023 | $-155.1M | 2022-12-01 – 2023-11-30 | evidence 0001549595-24-000025 |
| FY 2022 | $-183.9M | 2021-12-01 – 2022-11-30 | evidence 0001549595-23-000021 |
| FY 2021 | $-117.9M | 2020-12-01 – 2021-11-30 | evidence 0001564590-22-003007 |
| FY 2020 | $-65.0M | 2019-12-01 – 2020-11-30 | evidence 0001564590-21-006071 |
| FY 2019 | $-22.2M | 2018-12-01 – 2019-11-30 | evidence 0001564590-21-006071 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).